Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has agreed to acquire privately held Actio Biosciences, Inc. for $820 million upfront and up ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE